Cargando…

Skin manifestations in spondyloarthritis

Spondyloarthritides (SpA) like psoriatic arthritis, axial spondyloarthritis/ankylosing spondylitis, reactive arthritis and inflammatory bowel disease (IBD)-associated SpA can present with characteristic skin manifestations. These SpA-associated skin disorders may precede joint involvement, reflect a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Meier, Katharina, Schloegl, Alexandra, Poddubnyy, Denis, Ghoreschi, Kamran
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Extra-Articular Manifestations and Comorbidities in Spondyloarthritis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7727049/ https://www.ncbi.nlm.nih.gov/pubmed/33343725 http://dx.doi.org/10.1177/1759720X20975915

Ejemplares similares

The impact of extra-musculoskeletal manifestations on disease activity, functional status, and treatment patterns in patients with axial spondyloarthritis: results from a nationwide population-based study
por: Redeker, Imke, et al.
Publicado: (2020)

Uveitis in spondyloarthritis
por: Rademacher, Judith, et al.
Publicado: (2020)

IBD considerations in spondyloarthritis
por: Di Jiang, Caroline, et al.
Publicado: (2020)

Multidisciplinary working in the management of axial and peripheral spondyloarthritis
por: Gudu, Tania, et al.
Publicado: (2020)

Risk of community-acquired pneumonia requiring hospitalization in patients with spondyloarthritis
por: Chung, Ho Yin, et al.
Publicado: (2020)

Mast cells in spondyloarthritis, more than simple inflammatory bystanders?
por: Polivka, Laura, et al.
Publicado: (2020)

Cardiovascular risk in patients with spondyloarthritis and association with anti-TNF drugs
por: Chan, Shirley Chiu Wai, et al.
Publicado: (2021)

Depression in patients with spondyloarthritis: prevalence, incidence, risk factors, mechanisms and management
por: Parkinson, Joel T., et al.
Publicado: (2020)

Loss and gain of bone in spondyloarthritis: what drives these opposing clinical features?
por: Clunie, Gavin, et al.
Publicado: (2020)

Potential relation of cardiovascular risk factors to disease activity in patients with axial spondyloarthritis
por: Ferraz-Amaro, Iván, et al.
Publicado: (2021)

Assessment of the relationship between estimated cardiovascular risk and structural damage in patients with axial spondyloarthritis
por: Ladehesa-Pineda, María Lourdes, et al.
Publicado: (2020)

Immunomodulation with IL-17 and TNF-α in spondyloarthritis: focus on the eye and the central nervous system
por: How Shing Koy, Elsa, et al.
Publicado: (2021)

Higher depression rates and similar cardiovascular comorbidity in psoriatic arthritis compared with rheumatoid arthritis and diabetes mellitus
por: Fragoulis, George E., et al.
Publicado: (2020)

Psoriatic arthritis and the association with cardiometabolic disease: a narrative review
por: Karmacharya, Paras, et al.
Publicado: (2021)

Increased risk of valvular heart disease in patients with ankylosing spondylitis: a nationwide population-based longitudinal cohort study
por: Siao, Wun-Zhih, et al.
Publicado: (2021)

Association of C-reactive protein and non-steroidal anti-inflammatory drugs with cardiovascular events in patients with psoriatic arthritis: a time-dependent Cox regression analysis
por: Lam, Steven H., et al.
Publicado: (2021)

Reduction of anterior uveitis flares in patients with axial spondyloarthritis on certolizumab pegol treatment: final 2-year results from the multicenter phase IV C-VIEW study
por: van der Horst-Bruinsma, Irene E., et al.
Publicado: (2021)

Early identification of axial psoriatic arthritis among patients with psoriasis: a prospective multicentre study
por: Proft, Fabian, et al.
Publicado: (2022)

Patient‐Reported Impact of Axial Spondyloarthritis on Working Life: Results From the European Map of Axial Spondyloarthritis Survey
por: Garrido‐Cumbrera, Marco, et al.
Publicado: (2021)

Diagnostic accuracy of inflammatory back pain for axial spondyloarthritis in rheumatological care
por: Poddubnyy, Denis, et al.
Publicado: (2018)

Impact of axial spondyloarthritis on mental health in Europe: results from the EMAS study
por: Garrido-Cumbrera, Marco, et al.
Publicado: (2021)

Treatment with tumour necrosis factor inhibitors is associated with a time-shifted retardation of radiographic spinal progression in patients with axial spondyloarthritis
por: Torgutalp, Murat, et al.
Publicado: (2022)

Predictive value of C-reactive protein for radiographic spinal progression in axial spondyloarthritis in dependence on genetic determinants of fibrin clot formation and fibrinolysis
por: Hoppe, Berthold, et al.
Publicado: (2021)

Recapture and retreatment rates with ixekizumab after withdrawal of therapy in patients with axial spondyloarthritis: results at week 104 from a randomised placebo-controlled withdrawal study
por: Landewé, Robert B M, et al.
Publicado: (2023)

Improvement of Signs and Symptoms of Nonradiographic Axial Spondyloarthritis in Patients Treated With Secukinumab: Primary Results of a Randomized, Placebo‐Controlled Phase III Study
por: Deodhar, Atul, et al.
Publicado: (2020)

Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: efficacy and safety results from a placebo-controlled, randomised withdrawal study (COAST-Y)
por: Landewé, Robert BM, et al.
Publicado: (2021)

Comorbidity management in spondyloarthritis
por: López-Medina, Clementina, et al.
Publicado: (2020)

Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials
por: van der Heijde, Désirée, et al.
Publicado: (2023)

Evaluation of multiple referral strategies for axial spondyloarthritis in the SPondyloArthritis Caught Early (SPACE) cohort
por: Abawi, Ozair, et al.
Publicado: (2017)

Prevalence and distribution of peripheral musculoskeletal manifestations in spondyloarthritis including psoriatic arthritis: results of the worldwide, cross-sectional ASAS-PerSpA study
por: López-Medina, Clementina, et al.
Publicado: (2021)

Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen‐Week Results From a Phase III Randomized, Double‐Blind, Placebo‐Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors
por: Deodhar, Atul, et al.
Publicado: (2019)

Impact of extra-articular spondyloarthritis manifestations and comorbidities on drug retention of a first TNF-inhibitor in ankylosing spondylitis: a population-based nationwide study
por: Lindström, Ulf, et al.
Publicado: (2018)

Serum inflammatory biomarkers fail to identify early axial spondyloarthritis: results from the SpondyloArthritis Caught Early (SPACE) cohort
por: Turina, Maureen C, et al.
Publicado: (2017)

Predictors of extra-articular manifestations in axial spondyloarthritis and their influence on TNF-inhibitor prescribing patterns: results from the British Society for Rheumatology Biologics Register in Ankylosing Spondylitis
por: Derakhshan, Mohammad H, et al.
Publicado: (2020)

Progression From Subclinical Inflammation to Overt Spondyloarthritis in First‐Degree Relatives of Patients in Association With HLA–B27: The Pre‐Spondyloarthritis Cohort
por: de Jong, Henriëtte M. Y., et al.
Publicado: (2022)

Peripheral spondyloarthritis: a neglected entity—state of the art
por: Carron, Philippe, et al.
Publicado: (2020)

The frequency of uveitis in patients with adult versus childhood spondyloarthritis
por: Turk, Matthew, et al.
Publicado: (2020)

Biomechanics in the onset and severity of spondyloarthritis: a force to be reckoned with
por: Iyer, Priyanka, et al.
Publicado: (2023)

Randomized Controlled Trial of Adalimumab in Patients With Nonpsoriatic Peripheral Spondyloarthritis
por: Mease, Philip, et al.
Publicado: (2015)

To move or not to move: the paradoxical effect of physical exercise in axial spondyloarthritis
por: Perrotta, Fabio Massimo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8ga0nkmgi84dpdtnu67eiu5uga